Department of Pathology and Laboratory Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Cancer Epidemiol Biomarkers Prev. 2022 Jul 1;31(7):1341-1350. doi: 10.1158/1055-9965.EPI-21-1312.
Immunotherapy is a rapidly evolving treatment option in breast cancer; However, the breast cancer immune microenvironment is understudied in Black and younger (<50 years) patients.
We used histologic and RNA-based immunoprofiling methods to characterize the breast cancer immune landscape in 1,952 tumors from the Carolina Breast Cancer Study (CBCS), a population-based study that oversampled Black (n = 1,030) and young women (n = 1,039). We evaluated immune response leveraging markers for 10 immune cell populations, compared profiles to those in The Cancer Genome Atlas (TCGA) Project [n = 1,095 tumors, Black (n = 183), and young women (n = 295)], and evaluated in association with clinical and demographic variables, including recurrence.
Consensus clustering identified three immune clusters in CBCS (adaptive-enriched, innate-enriched, or immune-quiet) that varied in frequency by race, age, tumor grade and subtype; however, only two clusters were identified in TCGA, which were predominantly comprised of adaptive-enriched and innate-enriched tumors. In CBCS, the strongest adaptive immune response was observed for basal-like, HER2-positive (HER2+), triple-negative breast cancer (TNBC), and high-grade tumors. Younger patients had higher proportions of adaptive-enriched tumors, particularly among estrogen receptor (ER)-negative (ER-) cases. Black patients had higher frequencies of both adaptive-enriched and innate-enriched tumors. Immune clusters were associated with recurrence among ER- tumors, with adaptive-enriched showing the best and innate-enriched showing the poorest 5-year recurrence-free survival.
These data suggest that immune microenvironments are intricately related to race, age, tumor subtype, and grade.
Given higher mortality among Black and young women, more defined immune classification using cell-type-specific panels could help explain higher recurrence and ultimately lead to targetable interventions.
免疫疗法是乳腺癌治疗的一种快速发展的选择;然而,在黑人患者和年轻患者(<50 岁)中,乳腺癌的免疫微环境研究不足。
我们使用组织学和基于 RNA 的免疫分析方法,对来自基于人群的卡罗来纳乳腺癌研究(CBCS)的 1952 个肿瘤的乳腺癌免疫图谱进行了特征描述,该研究对黑人(n=1030)和年轻女性(n=1039)进行了超额采样。我们利用 10 种免疫细胞群体的标志物来评估免疫反应,将这些特征与癌症基因组图谱(TCGA)项目中的特征进行比较(n=1095 个肿瘤,黑人(n=183)和年轻女性(n=295)),并评估其与临床和人口统计学变量(包括复发)的关联。
共识聚类确定了 CBCS 中的三个免疫簇(适应性富集、固有富集或免疫安静),它们的频率因种族、年龄、肿瘤分级和亚型而异;然而,TCGA 只识别了两个簇,主要由适应性富集和固有富集肿瘤组成。在 CBCS 中,基底样、HER2 阳性(HER2+)、三阴性乳腺癌(TNBC)和高级别肿瘤观察到最强的适应性免疫反应。年轻患者具有更高比例的适应性富集肿瘤,尤其是在雌激素受体(ER)阴性(ER-)病例中。黑人患者具有更高比例的适应性富集和固有富集肿瘤。免疫簇与 ER-肿瘤的复发有关,其中适应性富集表现最好,固有富集表现最差,5 年无复发生存率最差。
这些数据表明,免疫微环境与种族、年龄、肿瘤亚型和分级密切相关。
鉴于黑人患者和年轻女性的死亡率较高,使用细胞类型特异性面板进行更明确的免疫分类可能有助于解释更高的复发率,并最终导致可靶向的干预措施。